Borrowing information across patient subgroups in clinical trials, with application to a paediatric trial.
Bayesian analysis
Borrowing information
Paediatric trials
Small samples
Subgroups
Journal
BMC medical research methodology
ISSN: 1471-2288
Titre abrégé: BMC Med Res Methodol
Pays: England
ID NLM: 100968545
Informations de publication
Date de publication:
20 02 2022
20 02 2022
Historique:
received:
29
04
2021
accepted:
09
02
2022
entrez:
21
2
2022
pubmed:
22
2
2022
medline:
22
3
2022
Statut:
epublish
Résumé
Clinical trial investigators may need to evaluate treatment effects in a specific subgroup (or subgroups) of participants in addition to reporting results of the entire study population. Such subgroups lack power to detect a treatment effect, but there may be strong justification for borrowing information from a larger patient group within the same trial, while allowing for differences between populations. Our aim was to develop methods for eliciting expert opinions about differences in treatment effect between patient populations, and to incorporate these opinions into a Bayesian analysis. We used an interaction parameter to model the relationship between underlying treatment effects in two subgroups. Elicitation was used to obtain clinical opinions on the likely values of the interaction parameter, since this parameter is poorly informed by the data. Feedback was provided to experts to communicate how uncertainty about the interaction parameter corresponds with relative weights allocated to subgroups in the Bayesian analysis. The impact on the planned analysis was then determined. The methods were applied to an ongoing non-inferiority trial designed to compare antiretroviral therapy regimens in 707 children living with HIV and weighing ≥ 14 kg, with an additional group of 85 younger children weighing < 14 kg in whom the treatment effect will be estimated separately. Expert clinical opinion was elicited and demonstrated that substantial borrowing is supported. Clinical experts chose on average to allocate a relative weight of 78% (reduced from 90% based on sample size) to data from children weighing ≥ 14 kg in a Bayesian analysis of the children weighing < 14 kg. The total effective sample size in the Bayesian analysis was 386 children, providing 84% predictive power to exclude a difference of more than 10% between arms, whereas the 85 younger children weighing < 14 kg provided only 20% power in a standalone frequentist analysis. Borrowing information from a larger subgroup or subgroups can facilitate estimation of treatment effects in small subgroups within a clinical trial, leading to improved power and precision. Informative prior distributions for interaction parameters are required to inform the degree of borrowing and can be informed by expert opinion. We demonstrated accessible methods for obtaining opinions.
Sections du résumé
BACKGROUND
Clinical trial investigators may need to evaluate treatment effects in a specific subgroup (or subgroups) of participants in addition to reporting results of the entire study population. Such subgroups lack power to detect a treatment effect, but there may be strong justification for borrowing information from a larger patient group within the same trial, while allowing for differences between populations. Our aim was to develop methods for eliciting expert opinions about differences in treatment effect between patient populations, and to incorporate these opinions into a Bayesian analysis.
METHODS
We used an interaction parameter to model the relationship between underlying treatment effects in two subgroups. Elicitation was used to obtain clinical opinions on the likely values of the interaction parameter, since this parameter is poorly informed by the data. Feedback was provided to experts to communicate how uncertainty about the interaction parameter corresponds with relative weights allocated to subgroups in the Bayesian analysis. The impact on the planned analysis was then determined.
RESULTS
The methods were applied to an ongoing non-inferiority trial designed to compare antiretroviral therapy regimens in 707 children living with HIV and weighing ≥ 14 kg, with an additional group of 85 younger children weighing < 14 kg in whom the treatment effect will be estimated separately. Expert clinical opinion was elicited and demonstrated that substantial borrowing is supported. Clinical experts chose on average to allocate a relative weight of 78% (reduced from 90% based on sample size) to data from children weighing ≥ 14 kg in a Bayesian analysis of the children weighing < 14 kg. The total effective sample size in the Bayesian analysis was 386 children, providing 84% predictive power to exclude a difference of more than 10% between arms, whereas the 85 younger children weighing < 14 kg provided only 20% power in a standalone frequentist analysis.
CONCLUSIONS
Borrowing information from a larger subgroup or subgroups can facilitate estimation of treatment effects in small subgroups within a clinical trial, leading to improved power and precision. Informative prior distributions for interaction parameters are required to inform the degree of borrowing and can be informed by expert opinion. We demonstrated accessible methods for obtaining opinions.
Identifiants
pubmed: 35184739
doi: 10.1186/s12874-022-01539-3
pii: 10.1186/s12874-022-01539-3
pmc: PMC8858505
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
49Subventions
Organisme : Medical Research Council
ID : MC_UU_12023/23
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00004/03
Pays : United Kingdom
Organisme : UK Medical Research Council
ID : MC_UU_12023/21
Organisme : Medical Research Council
ID : MC_UU_00004/07
Pays : United Kingdom
Organisme : UK Medical Research Council
ID : MC_UU_12023/26
Informations de copyright
© 2022. The Author(s).
Références
Pharm Stat. 2016 Mar-Apr;15(2):123-34
pubmed: 26685103
Health Serv Outcomes Res Methodol. 2016;16(4):213-233
pubmed: 27881932
Stat Methods Med Res. 2018 Feb;27(2):398-413
pubmed: 26994211
J Clin Epidemiol. 2010 Apr;63(4):355-69
pubmed: 19716263
Clin Trials. 2017 Aug;14(4):357-367
pubmed: 28675302
Clin Trials. 2017 Oct;14(5):451-461
pubmed: 28830236
Biometrics. 2011 Sep;67(3):1047-56
pubmed: 21361892
Clin Trials. 2018 Apr;15(2):149-158
pubmed: 29499621
J Clin Epidemiol. 2010 Apr;63(4):370-83
pubmed: 19926253
BMC Infect Dis. 2021 Jan 4;21(1):5
pubmed: 33446115
Stat Med. 2001 Feb 28;20(4):581-600
pubmed: 11223902
Ann Oncol. 2017 Jan 1;28(1):34-43
pubmed: 28177494
Clin Trials. 2013 Oct;10(5):720-34
pubmed: 23983156
Clin Trials. 2011 Apr;8(2):129-43
pubmed: 21282293
J Med Philos. 1986 Nov;11(4):385-404
pubmed: 3819606
Biometrics. 2014 Dec;70(4):1023-32
pubmed: 25355546